Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27190163 | 0.87 | ADORA1 (0.48) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL24633308 | 0.81 | RNASEL (0.49) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL20911313 | 0.81 | RNASEL (0.49) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL23195177 | 0.81 | RNASEL (0.49) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL3828789 | 0.80 | P2RY1 (0.92) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL290977 | 0.80 | P2RY1 (0.90) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| Vidarabine Phosphate SCHEMBL7111227 | 0.80 | P2RY1 (0.90) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL23647917 | 0.78 | ADORA1 (0.75) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL20942825 | 0.78 | ADORA1 (0.75) | P2RY1P2RY2SRCADORA1SMN1; SMN2 | |
| SCHEMBL29388941 | 0.78 | ADORA1 (0.75) | P2RY1P2RY2SRCADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952574-B2 | Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression | NOVO NORDISK A/S (DK) | 2024-04-09 | — | — | US | disclosed |
| US-20230220398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION | NOVO NORDISK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655473-B2 | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression | NOVO NORDISK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION | NR1H3, NR1H2, NR1H4 | P2RY1 4195/4885P2RY2 4211/4885SRC 3500/4885 |
| US-11952574-B2 | Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression | TMPRSS6, TMPRSS4, TMPRSS11D | P2RY1 4090/4885P2RY2 4064/4885SRC 4642/4885 |
| US-11655473-B2 | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression | MRM1, POLRMT, ARG2 | P2RY1 3686/4885P2RY2 4384/4885SRC 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.